Antagonism of behavioral effects of cocaine by selective dopamine receptor blockers

1990 ◽  
Vol 101 (1) ◽  
pp. 142-145 ◽  
Author(s):  
Roger D. Spealman
Keyword(s):  
Dopamine Receptor ◽  
Behavioral Effects ◽  
Receptor Blockers ◽  
Selective Dopamine

scholarly journals Cellular and Behavioral Effects of D2 Dopamine Receptor Hydrophobic Eigenmode-Targeted Peptide Ligands

2003 ◽  
Vol 28 (S1) ◽  
pp. S98-S107 ◽  
Author(s):  
Arnold J Mandell ◽  
Karen A Selz ◽  
Michael J Owens ◽  
Becky Kinkead ◽  
Michael F Shlesinger ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Peptide Ligands ◽  
Behavioral Effects ◽  
D2 Dopamine Receptor

Zetidoline, A New Antipsychotic

1984 ◽  
Vol 145 (3) ◽  
pp. 294-299 ◽  
Author(s):  
T. Silverstone ◽  
S. Levine ◽  
H. L. Freeman ◽  
A. Dubini
Keyword(s):  
Side Effects ◽  
Dopamine Receptor ◽  
Blind Study ◽  
Double Blind Study ◽  
Extrapyramidal Side Effects ◽  
Double Blind ◽  
Receptor Blocking ◽  
Selective Dopamine

SummaryZetidoline (ZTD), a compound chemically unrelated to any available antipsychotic, with selective dopamine receptor-blocking properties, was compared with haloperidol (HLP) in a double-blind study on 56 in-patients who had either first episodes or acute relapses of schizophrenia. ZTD was found to be safe, as effective as HLP, and to produce significantly fewer extrapyramidal side-effects (EPS).

Design and synthesis of a piperazinylalkylisoxazole library for subtype selective dopamine receptor ligands

2002 ◽  
Vol 12 (10) ◽  
pp. 1327-1330 ◽  
Author(s):  
Mi Young Cha ◽  
Byung Chul Choi ◽  
Kyung Ho Kang ◽  
Ae Nim Pae ◽  
Kung Il Choi ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
Receptor Ligands ◽  
Design And Synthesis ◽  
Subtype Selective ◽  
Selective Dopamine

scholarly journals Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease

2002 ◽  
Vol 13 (3-4) ◽  
pp. 117-121 ◽  
Author(s):  
Kazuo Abe ◽  
Mayako Takanashi ◽  
Takehiko Yanagihara ◽  
Sabro Sakoda
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Dopamine Receptor ◽  
Rating Scale ◽  
D1 Receptor ◽  
Dopamine Receptor Agonist ◽  
Functional Correlation ◽  
Yahr Scale ◽  
Disease Rating ◽  
Selective Dopamine

Objectives:Fatigue is a complaint frequently encountered among patients with Parkinson’s disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 dopamine receptor agonist) and bromocriptine (a D2 selective dopamine receptor) in patients with PD.Methods:We evaluated 41 patients with PD and controls. We assessed the degree of fatigue by using a fatigue scale. The severity of PD was evaluated by the Hoehn and Yahr Scale and the unified Parkinson’s disease rating scale (UPDRS).Results:After five weeks from prescription, patients taking pergolide mesilate showed significant improvement in the fatigue scale (from 5.1 ± 0.7 to 4.4 ± 0.55,p< 0.05, ) but patients taking bromocriptine did not (from 4.8 ± 0.9 to 4.7 ± 0.8).Conclusions:Our study suggested the possibility of functional correlation between fatigue and D1 receptor in patients with PD.

Sign in / Sign up

Export Citation Format

Share Document